Lipoprotein Receptor, Very Low Density (VLDLR)

586 EUR

200ug

GEN609597

N/A

N/A

N/A

N/A

IgG1

9L449

Antibodies

Monoclonal

Mouse (Mus musculus)

Mnoclonal antibodies

Human (Homo sapiens)

ELISA (EL/EIA), Western Blot (WB)

Lipoprotein Receptor, Very Low Density

Affinity Purified by Protein A affinity chromatography.

low density lipoprotein receptor related protein-deleted in tumor; N/A

Supplied as a liquid in 0.05M sodium phosphate, 0.1M sodium chloride, 1mM EDTA, pH 6.6. No preservative added

Human (Homo sapiens); Due to limited knowledge and inability for testing each and every species, the reactivity of the antibody may extend to other species which are not listed hereby.

Recognizes human Very Low Density Lipoprotein (VLDL) receptor (aa31-355).; Since it is not possible to test each and every species our knowledge on the corss reactivity of the antibodies is limited. This particular antibody might cross react with speacies outside of the listed ones.

Store the antibody at +4 degrees Celsius for short term storage.. Aliquot to avoid repeated freezing and thawing. For optimal long term storage, the antibody should be kept at -20 degrees Celsius. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

High and low density proteins are supplied by MBS Monoclonals in volumes of 1. Other densities are possible.The receptors are ligand binding factors of type 1, 2 or 3 and protein-molecules that receive chemical-signals from outside a cell. When such chemical-signals couple or bind to a receptor, they cause some form of cellular/tissue-response, e.g. a change in the electrical-activity of a cell. In this sense, am olfactory receptor is a protein-molecule that recognizes and responds to endogenous-chemical signals, chemokinesor cytokines e.g. an acetylcholine-receptor recognizes and responds to its endogenous-ligand, acetylcholine. However, sometimes in pharmacology, the term is also used to include other proteins that are drug-targets, such as enzymes, transporters and ion-channels.